| Price and Chart delayed at least 15 mintues. |
|
Price
$ 53.15
|
Change
0.00
|
|
Open
0.00
|
% Change
0.0%
|
|
Prev Close
53.15
|
Volume
NA
|
|
Market Value
32 bil
|
P/E Ratio
16.0
|
|
Bid
47.16
|
EPS
3.33
|
|
Ask
0.00
|
Dividend
1.04
|
|
High
0.00
|
Yield
2.0
|
|
Low
0.00
|
Shares Out
605 mil
|
|
52wk High
71.53
|
52wk Low
45.46
|
|
Industry: Medical Instruments & Supplies
|
|
Sector: Healthcare
|
BAX Profile
A global, healthcare company, which develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.
Baxter Internat, Inc.
One Baxter Parkway
Deerfield, IL 60015-4633
Phone: (847) 948-2000
Fax: (847) 948-3642
Web Site: www.baxter.com
BAX Wires Headlines
|
|
| 07.02.09 |
|
Final Glance: Pharmaceuticals companies
|
|
| 07.02.09 |
|
Final Glance: Medical Devices companies
|
|
| 07.02.09 |
|
Midday Glance: Pharmaceuticals companies
|
|
| 07.02.09 |
|
Midday Glance: Medical Devices companies
|
|
| 07.02.09 |
|
Early Glance: Pharmaceuticals companies
|
More BAX From Wires Headlines >
Forbes.com on BAX RSS
No news found in the past 30 days.BAX Press Releases
|
|
| 06.22.09 |
|
Critical Alerts for GOOG, BK, BAX, COH, and HST Released by Seven Summits Research |
|
| 06.18.09 |
|
Baxter Highlights Progress Toward Sustainability Priorities in 10th Annual Sustainability Report |
|
| 06.18.09 |
|
Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating... |
|
| 06.12.09 |
|
Baxter Advances to Full-Scale Production of A/H1N1 Vaccine |
More BAX Press Releases >
BAX Ratios & Returns
| Price-to-sales |
2.62 |
| Return on Equity |
34.5 |
| Operating Margin |
26.9 |
| Profit Margin |
17.1% |
More BAX Ratios & Returns >
BAX Financials
| Sales |
$12.295 bil |
| Profits |
$2.103 bil |
| Assets |
$14.953 bil |
| Employees |
48500.0 |
|
|
|
Baxter International is ranked # 342 on the 2009 Forbes 2000 List
|
|
Thomson / IBES Earnings Estimates on BAX
Accounting Risk
Buy/Hold/Sell Analysis
Forbes Investment Guru Commentary on BAX
RSS News Feed on BAX
|
A D V E R T I S E M E N T
|